Form 4 for XLO Xilio Therapeutics, Inc.
Accepted 2025-01-03 00:00:00 ET · period of report 2025-01-01 · accession 0001415889-25-000407 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-03 | 2025-01-01 | XLO | Frankenfield Christopher James | CFO | M - OptEx | — | +19.4K | 19.4K | New | — |
| D | 2025-01-03 | 2025-01-02 | XLO | Frankenfield Christopher James | CFO | S - Sale+OE | $0.98 | -6,954 | 12.4K | -36% | -$6,815 |
| D | 2025-01-03 | 2025-01-01 | XLO | Frankenfield Christopher James | CFO | A - Grant | $0.00 | +251.0K | 251.0K | New | $0 |
| D | 2025-01-03 | 2025-01-01 | XLO | Frankenfield Christopher James | CFO | M - OptEx | $0.00 | -19.4K | 58.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-01 | M | A | 19,375 | — | 19,375 | D | — | — | (F1) Restricted stock units ("RSUs) convert to stock on a one-for-one basis |
| 2 | Common | Common stock | 2025-01-02 | S | D | 6,954 | $0.98 | 12,421 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-01-01 | A | A | 251,000 | $0.00 | 251,000 | D | $0.96 · — to 2035-12-31 | 251,000 Common Stock | (F4) The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029. |
| 4 | Derivative | Restricted Stock Units | 2025-01-01 | M | D | 19,375 | $0.00 | 58,125 | D | — · — to — | 19,375 Common Stock | (F1) Restricted stock units ("RSUs) convert to stock on a one-for-one basis (F3) These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. |